PCM
KERX

Prelude Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Prelude Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,000
Closed -$51K – 2295
2014
Q1 		$51K Buy
+3,000
New +$45.3K 0.01% 1304

Prelude Capital Management's KERX Position: Q4 2018 in Review

Prelude Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 1,495 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in KERX in Q2 2013 and held it in 13 quarters. The position peaked at $1.65M in Q4 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Prelude Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 1,495 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $5K.
  • Prelude Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • Prelude Capital Management's Keryx Biopharmaceuticals Inc position peaked at $1.65M in Q4 2013.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.